A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Consensus on the lung cancer management after third-generation EGFR-TKI resistance. | LitMetric

AI Article Synopsis

  • Lung cancer is the most common type of cancer in the Asia-Pacific region, with non-small cell lung cancer (NSCLC) making up about 85% of cases, and a significant mutation rate of 40-60% in Asian patients with lung adenocarcinoma.
  • Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved treatment for NSCLC with mutations, but managing resistance to these drugs is still a major issue with no standardized guidelines.
  • A set of recommendations has been developed, integrating international guidelines and regional clinical experiences, to help healthcare providers classify resistance, conduct clinical testing, and devise treatment strategies for patients struggling with resistance to third-generation EGFR-TKIs.

Article Abstract

Lung cancer is the most prevalent malignant tumour in the Asia-Pacific region. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers. Among these, the rate of mutations in Asian patients with lung adenocarcinoma is 40-60%. Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) have improved the clinical management of NSCLC with mutations, but resistance to these drugs remains a significant challenge. Despite numerous ongoing studies, there is no standardized consensus on managing resistance to third-generation EGFR-TKIs. This consensus integrates international guidelines on EGFR-TKI management, findings from clinical studies, and experiences from the Asia-Pacific region in addressing post-resistance. Detailed recommendations are provided for classification and progression patterns, clinical testing, and post-resistance treatment strategies related to third-generation EGFR-TKI resistance. The aim of these recommendations is to offer reference opinions for the standardized management of patients exhibiting resistance to third-generation EGFR-TKIs in clinical practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697410PMC
http://dx.doi.org/10.1016/j.lanwpc.2024.101260DOI Listing

Publication Analysis

Top Keywords

lung cancer
12
third-generation egfr-tki
8
egfr-tki resistance
8
asia-pacific region
8
resistance third-generation
8
third-generation egfr-tkis
8
third-generation
5
resistance
5
consensus lung
4
management
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!